Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Jazz Pharmaceuticals has commenced patient enrollment in a Phase III clinical trial designed to evaluate the safety, efficacy and pharmacokinetics of Xyrem (sodium oxybate) in children and adolescents aged seven to 17 who have narcolepsy with cataplexy.
Subscribe to our email newsletter
Xyrem (sodium oxybate) oral solution, CIII, is indicated to treat cataplexy in narcolepsy and for the treatment of excessive daytime sleepiness (EDS) in narcolepsy.
The drug is the only FDA approved treatment for narcolepsy with cataplexy in adults and the approval was based on clinical data in primarily adult patients.
Around 100 pediatric patients globally at sites in the US and several countries in Europe will be enrolled in the 52-week, randomized, double-blind, open-label, multicenter Phase III Xyrem Pediatric Narcolepsy trial.
In three controlled clinical trials, the most common adverse reactions in Xyrem-treated patients were nausea, dizziness, vomiting, somnolence, enuresis and tremor.